Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2020

January 2020 | 199 pages | ID: HF437F372F3EN
Global Markets Direct

Abstracts

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2020, provides an overview of the Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline landscape.

Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 6, 6, 10, 1, 12, 3 and 1 respectively.

Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Hospital Acquired Pneumonia (HAP) - Overview
Hospital Acquired Pneumonia (HAP) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development
Aridis Pharmaceuticals Inc
AstraZeneca Plc
Auspherix Pty Ltd
Biolytx Pharmaceuticals Corp
Bioversys AG
Centauri Therapeutics Ltd
Cumberland Pharmaceuticals Inc
CytaCoat AB
Destiny Pharma Plc
Dong-A Socio Holdings Co Ltd
EnBiotix Inc
Evaxion Biotech ApS
Hypo-Stream Ltd
Meiji Seika Pharma Co Ltd
Merck & Co Inc
Motif Bio Plc
Nabriva Therapeutics Plc
Nosopharm SAS
Omnix Medical Ltd
Peptineo
Polyphor AG
Sealife PHARMA GMBH
Shionogi & Co Ltd
Spero Therapeutics Inc
Tetraphase Pharmaceuticals Inc
TGV-Inhalonix Inc
VenatoRx Pharmaceuticals Inc
Wockhardt Ltd
Hospital Acquired Pneumonia (HAP) - Drug Profiles
(avibactam + aztreonam) - Drug Profile
(avibactam sodium + ceftazidime) - Drug Profile
(cefepime + taniborbactam hydrochloride) - Drug Profile
Hospital Acquired Pneumonia (HAP) - Dormant Projects
Hospital Acquired Pneumonia (HAP) - Discontinued Products
Hospital Acquired Pneumonia (HAP) - Product Development Milestones
Featured News & Press Releases
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals Inc, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Auspherix Pty Ltd, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Biolytx Pharmaceuticals Corp, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Bioversys AG, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Centauri Therapeutics Ltd, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Cumberland Pharmaceuticals Inc, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by CytaCoat AB, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Plc, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by EnBiotix Inc, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Evaxion Biotech ApS, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Hypo-Stream Ltd, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co Inc, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics Plc, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Nosopharm SAS, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Omnix Medical Ltd, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Peptineo, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Polyphor AG, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Sealife PHARMA GMBH, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co Ltd, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Spero Therapeutics Inc, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by TGV-Inhalonix Inc, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by VenatoRx Pharmaceuticals Inc, H1 2020
Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Ltd, H1 2020
Hospital Acquired Pneumonia (HAP) - Dormant Projects, H1 2020
Hospital Acquired Pneumonia (HAP) - Dormant Projects, H1 2020 (Contd..1), H1 2020
Hospital Acquired Pneumonia (HAP) - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Aridis Pharmaceuticals Inc
AstraZeneca Plc
Auspherix Pty Ltd
Biolytx Pharmaceuticals Corp
Bioversys AG
Centauri Therapeutics Ltd
Cumberland Pharmaceuticals Inc
CytaCoat AB
Destiny Pharma Plc
Dong-A Socio Holdings Co Ltd
EnBiotix Inc
Evaxion Biotech ApS
Hypo-Stream Ltd
Meiji Seika Pharma Co Ltd
Merck & Co Inc
Motif Bio Plc
Nabriva Therapeutics Plc
Nosopharm SAS
Omnix Medical Ltd
Peptineo
Polyphor AG
Sealife PHARMA GMBH
Shionogi & Co Ltd
Spero Therapeutics Inc
Tetraphase Pharmaceuticals Inc
TGV-Inhalonix Inc
VenatoRx Pharmaceuticals Inc
Wockhardt Ltd